Marfan Syndrome

Overview

Marfan syndrome is an inherited connective-tissue disorder, usually caused by a disease-causing change in the FBN1 gene, which encodes fibrillin-1, a protein important for the body’s elastic tissues. It can affect the aorta and heart valves, eyes, skeleton, lungs, skin, and nervous system; severity varies greatly, from relatively mild disease to rapidly progressive neonatal forms. FBN1-Related Marfan Syndrome With specialized monitoring and treatment, life expectancy can approach that of the general population, although aortic enlargement, dissection, and rupture remain the principal life-threatening risks. FBN1-Related Marfan Syndrome

There is currently no therapy that corrects the underlying FBN1 alteration throughout the body. Standard care aims to prevent complications through lifelong aortic imaging, beta blockers and/or angiotensin-receptor blockers (ARBs, such as losartan), individualized activity advice, eye and orthopedic care, and preventive aortic-root surgery when risk thresholds are reached. 2022 ACC/AHA Aortic Disease Guideline Current guidelines recommend a maximally tolerated beta blocker or ARB to reduce aortic dilation; combining the two is considered reasonable in many patients. 2022 ACC/AHA Aortic Disease Guideline

Scope of Recent Research (2020–present)

Research activity since 2020 has been substantial but remains concentrated on preventing aortic damage rather than delivering a whole-body cure. The dominant questions are how distinct FBN1 variants damage the aortic wall, which downstream pathways can be safely modified, and whether RNA, gene-editing, or local gene-delivery technologies can restore fibrillin-1 function. Translational Medicine: Towards Gene Therapy of Marfan Syndrome The field has produced credible therapeutic leads and increasingly sophisticated human cell models, but no curative gene, RNA, or cell therapy has yet entered clinical use for Marfan syndrome. Therapeutic Opportunities of Marfan Syndrome

Major Breakthroughs and Emerging Therapies

RNA therapeutics. The most directly disease-targeted recent advance is a 2021 proof-of-concept for antisense oligonucleotides—short synthetic nucleic acids that alter RNA splicing. Researchers induced skipping of FBN1 exon 52 in cultured fibroblasts, aiming to make both copies of fibrillin-1 more alike and thereby allow assembly of microfibrils, the tissue scaffolds disrupted in Marfan syndrome. Antisense skipping of FBN1 exon 52 At high levels of exon skipping, fibrillin-1 fibers reappeared in the cell system, but the resulting shortened fibrillin-1 protein has not yet been proven functional in animals or people. Antisense skipping of FBN1 exon 52 This is a personalized strategy that would apply only to a limited subset of variants and requires a practical way to deliver repeated treatment to the aorta and other relevant tissues. Antisense skipping of FBN1 exon 52

Small molecules and pathway-modifying drugs. A 2023 screen of 1,022 compounds in patient-derived, induced pluripotent stem cell (iPSC)-derived vascular smooth-muscle cells identified 36 compounds that improved a disease-related excessive protein-degradation phenotype. iPSC screen identifies GSK3β Follow-up experiments implicated GSK3β, an intracellular signaling enzyme, as a potential target: its inhibition improved abnormal protein breakdown and cell survival and partly restored fibrillin-1 deposition in the laboratory model. iPSC screen identifies GSK3β This is an early target-discovery result, not evidence that a GSK3β inhibitor can yet prevent dissection or cure Marfan syndrome in patients. iPSC screen identifies GSK3β

Optimizing established signaling therapy. ARBs do not fix FBN1, but they remain the best-supported pharmacologic approach for slowing aortic-root growth. An individual-patient-data meta-analysis published in 2022 found that ARB allocation approximately halved the annual increase in aortic-root Z score versus control during a median three-year follow-up, with particularly large effects in participants with pathogenic FBN1 variants. ARB and beta-blocker meta-analysis A 2020 long-term follow-up of the COMPARE randomized trial also associated continued losartan use, alongside beta-blocker therapy, with fewer composite clinical events than control treatment. COMPARE long-term losartan follow-up These treatments are disease-modifying in the limited sense of reducing aortic risk; they are not curative and do not reverse the inherited defect. 2022 ACC/AHA Aortic Disease Guideline

Gene therapy and gene editing. Reviews of the translational field describe potential approaches including adeno-associated virus (AAV) delivery, locally applied vascular gene transfer, transcription-factor “decoys,” microRNA modulation, and CRISPR-based correction. Translational Medicine: Towards Gene Therapy of Marfan Syndrome However, Marfan syndrome presents an unusually difficult delivery problem because fibrillin-1 is needed across multiple tissues and because many FBN1 variants act through dominant-negative effects rather than simple absence of one protein copy. Therapeutic Opportunities of Marfan Syndrome Thus, current gene-editing work is best understood as a long-term research direction, not a near-clinic treatment option. Translational Medicine: Towards Gene Therapy of Marfan Syndrome

Clinical Trials and Experimental Approaches

The leading current disease-modifying drug trial is Valsar-TAD, a randomized, double-blind, placebo-controlled Phase III trial of valsartan in children and young adults with Marfan-type heritable thoracic aortic disease. Valsar-TAD trial record Sponsored by the Medical University of Gdańsk and supported by Poland’s Medical Research Agency, the study is recruiting in Poland, plans to enroll 180 participants, and measures annual aortic-root enlargement as its primary endpoint. Valsar-TAD trial record As of the registry update available for this report, no results have been posted. Valsar-TAD trial record

Other recent studies are supportive or exploratory rather than curative. For example, Washington University School of Medicine registered a small, not-yet-recruiting pilot study of a supervised ketogenic diet in 15 adults with Marfan syndrome and chronic or residual descending aortic dissection; participants would continue standard cardiovascular treatment while serial CT scans assess aortic change. Nutritional Ketosis Marfan No registered trial identified for this report is testing in vivo FBN1 correction, antisense exon skipping, or a Marfan-specific gene therapy in patients. Therapeutic Opportunities of Marfan Syndrome

Methodologies and Scientific Approaches

Researchers now combine animal models with human, patient-specific systems. iPSCs can be made from a patient’s cells and differentiated into vascular smooth-muscle cells, enabling researchers to test disease mechanisms and screen drugs in cells that reproduce key Marfan features, including impaired fibrillin-1 matrix deposition, excess proteolysis, and vulnerability to cell death. iPSC screen identifies GSK3β These systems are especially useful for comparing a patient’s original cells with genetically corrected “isogenic” control cells that differ principally at the disease-causing variant. Generation of Marfan patient-specific iPSCs

Aortic-tissue profiling has also become more precise. Single-cell RNA sequencing of human Marfan aneurysm tissue identified altered cell populations and dysfunctional transforming growth factor-beta (TGF-β) signaling, while mouse aortic single-cell studies have identified disease-associated smooth-muscle and endothelial-cell states that respond to losartan. Single-cell analysis of Marfan aorta Losartan-sensitive aortic transcriptomics These methods help distinguish molecular changes that cause disease from changes that merely accompany an established aneurysm.

Leading Institutions and Funding

Important contributors include the Medical University of Gdańsk and its Polish clinical partners, which are conducting the Phase III Valsar-TAD trial with support from the Medical Research Agency. Valsar-TAD trial record The University of Cambridge, Imperial College London, the Marfan Trust, and AstraZeneca collaborators produced the iPSC-derived vascular smooth-muscle-cell drug-screening platform that identified GSK3β as a candidate target. iPSC screen identifies GSK3β Murdoch University’s Molecular Therapy Laboratory has also supported antisense-therapy research for Marfan syndrome, including work by Jessica Cale on splice-switching approaches. Murdoch Molecular Therapy Laboratory

Patient-led funding remains important because Marfan syndrome is rare and lacks a large commercial gene-therapy pipeline. The Marfan Foundation reports funding more than $23 million in research since 1986; its current Innovators and Career Development awards provide $100,000 over two years, while its Victor McKusick Fellowship provides up to $150,000 over two years for an MD fellow. Marfan Foundation research grants Its funded-grants program has supported projects at institutions including Stanford and Johns Hopkins on Marfan aortic biology and valve disease. Marfan Foundation funded grants

Strengths, Limitations, and Challenges

The major strength of the field is that it now has clinically validated risk-reduction therapy, better human disease models, and several mechanistically plausible routes toward more precise treatment. ARB and beta-blocker meta-analysis iPSC screen identifies GSK3β The major limitation is that slowing aortic enlargement is fundamentally different from repairing defective fibrillin-1 throughout the aorta, valves, eye-supporting tissues, skeleton, and other organs. FBN1-Related Marfan Syndrome

Gene replacement is constrained by the large size of FBN1 and by the difficulty of reaching the right cells safely and durably; gene editing adds risks of unintended DNA changes, incomplete editing, immune reactions, and unequal benefit across the body. Translational Medicine: Towards Gene Therapy of Marfan Syndrome Variant diversity is another barrier: a treatment designed for one exon or one type of molecular defect may not help people with other FBN1 variants. Antisense skipping of FBN1 exon 52 Access is also a concern, since advanced individualized RNA or gene therapies could be expensive and require lifelong specialty follow-up even if they reduce aortic risk. Therapeutic Opportunities of Marfan Syndrome

Outlook and Future Directions

A cure for Marfan syndrome is not close as of August 8, 2026, but the field is moving beyond nonspecific blood-pressure control toward variant-aware RNA strategies, human-cell drug discovery, and aortic-cell mapping. Therapeutic Opportunities of Marfan Syndrome The most important near-term milestones are results from the Phase III Valsar-TAD trial, demonstration that FBN1 antisense strategies produce durable functional benefit in animal models, validation of targets such as GSK3β in vivo, and development of delivery systems that can safely reach the aortic wall. Valsar-TAD trial record Antisense skipping of FBN1 exon 52 Until then, early diagnosis, guideline-based medication, imaging surveillance, and timely preventive surgery remain the interventions most likely to save lives. 2022 ACC/AHA Aortic Disease Guideline

References

• FBN1-Related Marfan Syndrome — GeneReviews®, 2022.
• 2022 ACC/AHA Aortic Disease Guideline — American College of Cardiology/American Heart Association, 2022.
• Translational Medicine: Towards Gene Therapy of Marfan Syndrome — Köhler et al., 2022.
• Therapeutic Opportunities of Marfan Syndrome — Drug Design, Development and Therapy, 2025.
• Antisense skipping of FBN1 exon 52 — Cale et al., 2021.
• iPSC screen identifies GSK3β — Davaapil et al., 2023.
• ARB and beta-blocker meta-analysis — Pitcher et al., 2022.
• COMPARE long-term losartan follow-up — van Andel et al., 2020.
• Valsar-TAD trial record — EU Clinical Trials Information System, 2026.
• Nutritional Ketosis Marfan — Washington University School of Medicine, 2026.
• Generation of Marfan patient-specific iPSCs — Zhang et al., 2022.
• Single-cell analysis of Marfan aorta — Dawson et al., 2022.
• Losartan-sensitive aortic transcriptomics — Li et al., 2023.
• Murdoch Molecular Therapy Laboratory — Murdoch University, 2026.
• Marfan Foundation research grants — The Marfan Foundation, 2026.
• Marfan Foundation funded grants — The Marfan Foundation, 2026.